Skip to main content

Table 3 Categorization of clinical outcomes (ADHD symptoms and functionality)—exploratory subgroup analysis (n = 304)

From: A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice

Pre-initiation of GXR treatmenta Post-initiation of GXR treatmentb
  n Improvement No change Worsening
General Physician Symptom Assessment, n (%)*c
 Improvement 172 130 (75.6) 2 (1.2) 0 (0.0)
 No change 74 37 (50.0) 9 (12.2) 1 (1.4)
 Worsening 54 44 (81.5) 2 (3.7) 3 (5.6)
General Physician Functional Assessment, n (%)c
 Homelife*
  Improvement 132 102 (77.3) 4 (3.0) 1 (0.8)
  No change 118 52 (44.1) 9 (7.6) 2 (1.7)
  Worsening 48 34 (70.8) 9 (18.8) 1 (2.1)
 School performance*
  Improvement 161 111 (68.9) 3 (1.9) 0 (0.0)
  No change 89 45 (50.6) 11 (12.4) 2 (2.2)
  Worsening 44 33 (75.0) 5 (11.4) 2 (4.5)
  1. Exploratory subgroup analysis in a subgroup of patients who had received prior pharmacotherapy for ADHD
  2. ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release
  3. *P < 0.001, derived through extension of McNemar’s test (Bowker’s test)
  4. aOverall response to treatment regimen administered prior to GXR administration
  5. bThe best response registered while on treatment with GXR
  6. cPercentages were calculated using the corresponding categories under GXR treatment count as denominator; due to missing values, percentages in each category do not add up to 100%